Literature DB >> 1993014

Chemotherapy for oligodendroglioma. Progress report.

J G Cairncross1, D R Macdonald.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1993014     DOI： 10.1001/archneur.1991.00530140123026

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  13 in total

1.  Combined treatment modality for anaplastic oligodendroglioma: a phase II study.

Authors:  B Jeremic; Y Shibamoto; D Gruijicic; B Milicic; M Stojanovic; N Nikolic; A Dagovic; J Aleksandrovic
Journal:  J Neurooncol       Date:  1999-06       Impact factor: 4.130

2.  Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma.

Authors:  T J Postma; C J van Groeningen; R J Witjes; J G Weerts; J H Kralendonk; J J Heimans
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

3.  Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma.

Authors:  Bich-Ngoc-Thanh Tang; Niloufar Sadeghi; Fabrice Branle; Olivier De Witte; David Wikler; Serge Goldman
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

4.  High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.

Authors:  Lauren E Abrey; Barrett H Childs; Nina Paleologos; Lynne Kaminer; Steven Rosenfeld; Donna Salzman; Jonathan L Finlay; Sharon Gardner; Kendra Peterson; Wendy Hu; Lode Swinnen; Robert Bayer; Peter Forsyth; Douglas Stewart; Anne M Smith; David R Macdonald; Susan Weaver; David A Ramsey; Stephen D Nimer; Lisa M DeAngelis; J Gregory Cairncross
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

5.  Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas.

Authors:  Marc C Chamberlain
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

6.  The treatment of cerebral oligodendrogliomas with particular reference to features indicating malignancy: report of seventy-seven cases.

Authors:  M Turgut; K Tahta; O E Ozcan; B Onol
Journal:  Neurosurg Rev       Date:  1998       Impact factor: 3.042

7.  Aggressive oligodendroglioma predicted by chromosome 10 restriction fragment length polymorphism analysis. Case study.

Authors:  J K Wu; R D Folkerth; Z Ye; B T Darras
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

8.  High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.

Authors:  Lauren E Abrey; Barrett H Childs; Nina Paleologos; Lynne Kaminer; Steven Rosenfeld; Donna Salzman; Jonathan L Finlay; Sharon Gardner; Kendra Peterson; Wendy Hu; Lode Swinnen; Robert Bayer; Peter Forsyth; Douglas Stewart; Anne M Smith; David R Macdonald; Susan Weaver; David A Ramsay; Stephen D Nimer; Lisa M DeAngelis; J Gregory Cairncross
Journal:  Neuro Oncol       Date:  2006-03-08       Impact factor: 12.300

9.  A phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults.

Authors:  D J Stewart; S Dahrouge; K Soltys
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

10.  A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma.

Authors:  Karl Bélanger; David MacDonald; Gregory Cairncross; Stan Gertler; Peter Forsyth; Susan Burdette-Radoux; Julie Bergeron; Denis Soulières; Samuel Ludwin; Nancy Wainman; Elizabeth Eisenhauer
Journal:  Invest New Drugs       Date:  2003-11       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.